Skip to main content
Top
Published in: Journal of Medical Case Reports 1/2021

Open Access 01-12-2021 | Erectile Dysfunction | Case report

Abrupt-onset, profound erectile dysfunction in a healthy young man after initiating over-the-counter omeprazole: a case report

Author: Theodore W. Perry

Published in: Journal of Medical Case Reports | Issue 1/2021

Login to get access

Abstract

Background

Proton pump inhibitors are frequently used (and often overused) medications with adverse effects including vitamin B12 deficiency, Clostridium difficile colitis, and increased risk of chronic kidney disease. Erectile dysfunction is largely unrecognized as an adverse effect of proton pump inhibitors despite increasing evidence that proton pump inhibitors may contribute to impaired nitric oxide generation and endothelial dysfunction.

Case presentation

A 38-year-old Caucasian man with mild hypertension and no other significant medical history developed profound erectile dysfunction within 2 days of initiating over-the-counter omeprazole therapy, with erectile function rapidly normalizing following discontinuation of the drug. At the time of the episode, the patient was on a stable dose of lisinopril and was taking no other medications or supplements. In the 2 years following the episode, the patient has had no further erectile difficulties.

Conclusion

Further study of erectile dysfunction as an adverse effect of proton pump inhibitors is needed. In the meantime, proton pump inhibitors should be considered as a potential cause of erectile dysfunction in healthy young patients and as a cause or contributor to erectile dysfunction in older patients in whom erectile dysfunction is often attributed to age or comorbidities.
Literature
1.
go back to reference Shin JM, Cho YM, Sachs G. Chemistry of covalent inhibition of the gastric (H+, K+)-ATPase by proton pump inhibitors. J Am Chem Soc. 2004;126(25):7800.CrossRef Shin JM, Cho YM, Sachs G. Chemistry of covalent inhibition of the gastric (H+, K+)-ATPase by proton pump inhibitors. J Am Chem Soc. 2004;126(25):7800.CrossRef
2.
go back to reference Laine L, Ahnen D, McClain C, Solcia E, Welsh JH. Review article: potential gastrointestinal effects of long-term acid suppression with proton pump inhibitors. Aliment Pharmacol Ther. 2000;14(6):651.CrossRef Laine L, Ahnen D, McClain C, Solcia E, Welsh JH. Review article: potential gastrointestinal effects of long-term acid suppression with proton pump inhibitors. Aliment Pharmacol Ther. 2000;14(6):651.CrossRef
3.
go back to reference Cao F, Chen CX, Wang M, et al. Updated meta-analysis of controlled observational studies: proton-pump inhibitors and risk of Clostridium difficile infection. J Hosp Infect. 2018;98(1):4.CrossRef Cao F, Chen CX, Wang M, et al. Updated meta-analysis of controlled observational studies: proton-pump inhibitors and risk of Clostridium difficile infection. J Hosp Infect. 2018;98(1):4.CrossRef
4.
go back to reference Khalili H, Huang ES, Jacobson BC, Carmago CA, Feskanich D, Chan AT. Use of proton pump inhibitors and risk of hip fracture in relation to dietary and lifestyle factors: a prospective cohort study. BMJ. 2012;344:372.CrossRef Khalili H, Huang ES, Jacobson BC, Carmago CA, Feskanich D, Chan AT. Use of proton pump inhibitors and risk of hip fracture in relation to dietary and lifestyle factors: a prospective cohort study. BMJ. 2012;344:372.CrossRef
5.
go back to reference Lazarus B, Chen Y, Wilson FP, et al. Proton pump inhibitor use and the risk of chronic kidney disease. JAMA Intern Med. 2016;176(2):238.CrossRef Lazarus B, Chen Y, Wilson FP, et al. Proton pump inhibitor use and the risk of chronic kidney disease. JAMA Intern Med. 2016;176(2):238.CrossRef
6.
go back to reference Shiraev TP, Bullen A. Proton pump inhibitors and cardiovascular events: a systematic review. Heart Lung Circ. 2018;27(4):443–50.CrossRef Shiraev TP, Bullen A. Proton pump inhibitors and cardiovascular events: a systematic review. Heart Lung Circ. 2018;27(4):443–50.CrossRef
7.
go back to reference Selvin E, Burnett AL, Platz EA. Prevalence and risk factors for erectile dysfunction in the US. Am J Med. 2007;120(2):151.CrossRef Selvin E, Burnett AL, Platz EA. Prevalence and risk factors for erectile dysfunction in the US. Am J Med. 2007;120(2):151.CrossRef
8.
go back to reference Fung MM, Bettencourt R, Barrett-Connor E. Heart disease risk factors predict erectile dysfunction 25 years later: the Rancho Bernardo Study. J Am Coll Cardiol. 2004;43(8):1405.CrossRef Fung MM, Bettencourt R, Barrett-Connor E. Heart disease risk factors predict erectile dysfunction 25 years later: the Rancho Bernardo Study. J Am Coll Cardiol. 2004;43(8):1405.CrossRef
9.
go back to reference Grover SA, Lowensteyn I, Kaouache M, et al. The prevalence of erectile dysfunction in the primary care setting: importance of risk factors for diabetes and vascular disease. Arch Intern Med. 2006;166(2):213.CrossRef Grover SA, Lowensteyn I, Kaouache M, et al. The prevalence of erectile dysfunction in the primary care setting: importance of risk factors for diabetes and vascular disease. Arch Intern Med. 2006;166(2):213.CrossRef
10.
go back to reference Wein AJ, Van Arsdalen KN. Drug-induced male sexual dysfunction. Urol Clin North Am. 1988;15(1):23.CrossRef Wein AJ, Van Arsdalen KN. Drug-induced male sexual dysfunction. Urol Clin North Am. 1988;15(1):23.CrossRef
11.
go back to reference Grimm RH Jr, Grandits GA, Prineas RJ, et al. Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women. Treatment of Mild Hypertension Study (TOMHS). Hypertension. 1997;29(1 pt 1):8.CrossRef Grimm RH Jr, Grandits GA, Prineas RJ, et al. Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women. Treatment of Mild Hypertension Study (TOMHS). Hypertension. 1997;29(1 pt 1):8.CrossRef
12.
go back to reference Nolde M, Bahls M, Friedrich N, et al. Association of proton pump inhibitor use and metabolites of the nitric oxide pathway: a cross-sectional study. Pharmacotherapy. 2021;41(2):198–204.CrossRef Nolde M, Bahls M, Friedrich N, et al. Association of proton pump inhibitor use and metabolites of the nitric oxide pathway: a cross-sectional study. Pharmacotherapy. 2021;41(2):198–204.CrossRef
13.
go back to reference Pinheiro LC, Oliveira-Paula GH, Portella RL, Guimaraes DA, de Angelis CD, Tanus-Santos JE. Omeprazole impairs vascular redox biology and causes xanthine oxidoreductase-mediated endothelial dysfunction. Redox Biol. 2016;9:134–43.CrossRef Pinheiro LC, Oliveira-Paula GH, Portella RL, Guimaraes DA, de Angelis CD, Tanus-Santos JE. Omeprazole impairs vascular redox biology and causes xanthine oxidoreductase-mediated endothelial dysfunction. Redox Biol. 2016;9:134–43.CrossRef
14.
go back to reference Yepuri G, Sukhovershin R, Nazari-Shafti TZ, Petrascheck M, Ghebre YT, Cooke JP. Proton pump inhibitors accelerate endothelial senescence. Circ Res. 2016;118:e36–42.CrossRef Yepuri G, Sukhovershin R, Nazari-Shafti TZ, Petrascheck M, Ghebre YT, Cooke JP. Proton pump inhibitors accelerate endothelial senescence. Circ Res. 2016;118:e36–42.CrossRef
15.
go back to reference Omeprazole and erectile dysfunction—an update. Bijiwerkingen Centrum Lareb. Omeprazole and erectile dysfunction—an update. Bijiwerkingen Centrum Lareb.
16.
go back to reference Lindquist M, Edwards IR. Endocrine effects of omeprazole. BMJ. 1992;305(6851):451–2.CrossRef Lindquist M, Edwards IR. Endocrine effects of omeprazole. BMJ. 1992;305(6851):451–2.CrossRef
17.
go back to reference Sarioglu Y, Yildirim S, Utkan T, Yildirim MK, Uma S. Evidence of relaxant effect of omeprazole in rabbit corpus cavernosum in vitro. Life Sci. 2000;66(15):1411–21.CrossRef Sarioglu Y, Yildirim S, Utkan T, Yildirim MK, Uma S. Evidence of relaxant effect of omeprazole in rabbit corpus cavernosum in vitro. Life Sci. 2000;66(15):1411–21.CrossRef
18.
go back to reference Dayoub H, Achan V, Adimoolam S, et al. Dimethylarginine dimethylaminohydrolase regulates nitric oxide synthesis. Circulation. 2003;108:3042–7.CrossRef Dayoub H, Achan V, Adimoolam S, et al. Dimethylarginine dimethylaminohydrolase regulates nitric oxide synthesis. Circulation. 2003;108:3042–7.CrossRef
19.
go back to reference Batchelor R, Gilmartin JF, Kemp W, Hopper I, Liew D. Dementia, cognitive impairment and proton pump inhibitor therapy: a systematic review. J Gastroenterol Hepatol. 2017;32(8):1426.CrossRef Batchelor R, Gilmartin JF, Kemp W, Hopper I, Liew D. Dementia, cognitive impairment and proton pump inhibitor therapy: a systematic review. J Gastroenterol Hepatol. 2017;32(8):1426.CrossRef
Metadata
Title
Abrupt-onset, profound erectile dysfunction in a healthy young man after initiating over-the-counter omeprazole: a case report
Author
Theodore W. Perry
Publication date
01-12-2021
Publisher
BioMed Central
Published in
Journal of Medical Case Reports / Issue 1/2021
Electronic ISSN: 1752-1947
DOI
https://doi.org/10.1186/s13256-021-02981-5

Other articles of this Issue 1/2021

Journal of Medical Case Reports 1/2021 Go to the issue